Zydus Lifesciences's sickle cell drug gets USFDA's orphan designation
Business
Zydus Lifesciences just scored Orphan Drug Designation from the USFDA for Desidustat, its tablet for treating Sickle Cell Disease—a rare blood disorder with limited treatment options.
This move could be a game-changer for patients who've had very few choices so far.
Desidustat has already completed Phase II study
With this designation, Zydus gets perks like tax breaks, waived fees, and seven years of exclusive marketing if Desidustat is approved.
They've already wrapped up a Phase II study on the drug's safety and effectiveness, which will be published in a medical journal.
Even though the company's stock dipped after the news, this step could open new doors for both Zydus and people living with sickle cell.